Breast Cancer Trial, Recruiting NCT06053086 Sponsor: Institut du Cancer de Montpellier - Val d'Aurelle Condition: Breast Cancer
Back to Breast Cancer

Breast Cancer Trial, Recruiting

NCT06053086
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • Women aged 18 or older
  • People who have had breast-conserving surgery (removal of the tumour but not the whole breast) or full breast removal (mastectomy)
  • People whose cancer has spread to at least one nearby lymph node (called pN1 or higher), regardless of breast cancer type
  • People whose surgery removed all cancer with clear edges around it (no cancer cells found at the edges of the removed tissue)
  • People for whom doctors have recommended radiation treatment to the whole breast and nearby lymph nodes
  • People whose cancer has been confirmed to not have spread to other parts of the body
  • People whose individual risk of breast tissue hardening (fibrosis) from radiation has been assessed using a specific centralised test called the NovaGray RILA Breast® test
  • People who live close enough to the trial site to attend follow-up appointments
  • People who have signed and dated a consent form agreeing to take part
  • People enrolled in the French national social security system

Who may not be able to join:

  • People whose cancer has spread to distant parts of the body (metastases)
  • People who have or have had cancer in both breasts at the same time or previously, unless the other breast had only a very early, non-invasive change (called an in situ lesion)
  • People who have had another type of cancer (other than breast cancer) in the past 5 years, unless it was a common skin cancer (basal or squamous cell) or a very early cervical change — and people with a previous cancer must have been cancer-free for at least five years
  • People with serious ongoing health conditions affecting the heart, kidneys, liver, lungs, or other body systems that could prevent long-term follow-up
  • People who have taken part in another drug trial in the past 30 days (observational studies that only collect data may be acceptable — confirm with trial site)
  • People with an untreated underactive thyroid (hypothyroidism)
  • People known to be HIV positive
  • People known to have a rare genetic condition that makes them unusually sensitive to radiation (confirm with trial site)
  • People who are pregnant or breastfeeding
  • People who are unable to meet the study requirements for geographic, personal, or health reasons, or who are unable to understand what the study involves
  • People who are under legal guardianship, protective custody, or who have had their personal liberty restricted

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 19 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: BOURGIER CELINE, Institut du Cancer de Montpellier - Val d'Aurelle

Phone: 0467613102

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Institut du Cancer de Montpellier - Val d'Aurelle
Registry
ClinicalTrials.gov
Start date
1 March 2025
Est. completion
30 November 2030

Where this trial is recruiting

🇫🇷 France

Primary endpoints

Rate of patients without any grade 2 and more toxicities within the planning target volume

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 19 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov